Marksans Pharma Limited

NSEI:MARKSANS 주식 보고서

시가총액: ₹136.0b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Marksans Pharma 미래 성장

Future 기준 확인 4/6

Marksans Pharma (는) 각각 연간 21.6% 및 18.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 21.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16.9% 로 예상됩니다.

주요 정보

21.2%

수익 성장률

21.2%

EPS 성장률

Pharmaceuticals 수익 성장18.1%
매출 성장률16.3%
향후 자기자본 수익률18.1%
애널리스트 커버리지

Low

마지막 업데이트05 Sep 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

수익 및 매출 성장 예측

NSEI:MARKSANS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
3/31/202735,6905,9744,354N/A2
3/31/202631,1104,8233,460N/A3
3/31/202526,4183,8592,025N/A3
6/30/202422,6803,338N/AN/AN/A
3/31/202421,7743,1372162,304N/A
12/31/202321,0343,164N/AN/AN/A
9/30/202319,9712,9658942,528N/A
6/30/202319,1842,743N/AN/AN/A
3/31/202318,5212,6631,8382,374N/A
12/31/202217,8422,123N/AN/AN/A
9/30/202216,6702,0049721,286N/A
6/30/202215,7561,847N/AN/AN/A
3/31/202214,9081,868529993N/A
12/31/202114,0692,367N/AN/AN/A
9/30/202114,0262,4738831,336N/A
6/30/202114,0642,518N/AN/AN/A
3/31/202113,7622,3851,3221,786N/A
12/31/202013,8172,018N/AN/AN/A
9/30/202013,1421,7241,8392,478N/A
6/30/202012,2031,476N/AN/AN/A
3/31/202011,3441,2081,7342,333N/A
12/31/201910,463879N/AN/AN/A
9/30/20199,97283466416N/A
6/30/201910,099780N/AN/AN/A
3/31/201910,001804142274N/A
12/31/20189,523666N/AN/AN/A
9/30/20189,223582N/AN/AN/A
6/30/20189,272463N/AN/AN/A
3/31/20189,127358N/A501N/A
12/31/20178,918343N/AN/AN/A
9/30/20178,949275N/AN/AN/A
6/30/20178,015187N/AN/AN/A
3/31/20177,672113N/A141N/A
12/31/20167,92670N/AN/AN/A
9/30/20167,948136N/AN/AN/A
6/30/20168,699481N/AN/AN/A
3/31/20168,933785N/A308N/A
12/31/20158,5361,093N/AN/AN/A
9/30/20158,4951,191N/AN/AN/A
6/30/20158,0451,154N/AN/AN/A
3/31/20157,9671,094N/A1,545N/A
12/31/20147,850950N/AN/AN/A
9/30/20147,405897N/AN/AN/A
6/30/20146,914786N/AN/AN/A
3/31/20146,300719N/A648N/A
12/31/20135,9501,020N/AN/AN/A

애널리스트 미래 성장 예측

수입 대 저축률: MARKSANS 의 연간 예상 수익 증가율( 21.6% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: MARKSANS 의 연간 수익( 21.6% ) Indian 시장( 15.9% 보다 빠르게 성장할 것으로 예상됩니다. 15.9% 연간).

고성장 수익: MARKSANS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: MARKSANS 의 수익(연간 18.7% ) Indian 시장( 9.5% 보다 빠르게 성장할 것으로 예상됩니다. 9.5% 연간).

고성장 수익: MARKSANS 의 수익(연간 18.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MARKSANS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 16.9 %).

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y